9th DDR Inhibitors Summit

Returning to Boston for its 9th year, the DDR Inhibitors Summit is the definitive industry forum for drug developers advancing DNA Damage Response (DDR)-targeted therapies. With PARP inhibitors now clinically validated, the field is rapidly evolving to explore novel DDR targets like ATR, CHK1/2, DNA-PK, and WEE1, alongside smarter biomarker strategies and combination approaches.

This year's summit is your opportunity to stay ahead of the curve. Across three content-rich days, you'll uncover translational breakthroughs, hear from biotech innovators and academic pioneers, and gain strategic insights to overcome resistance, enhance selectivity, and accelerate clinical success. With the DDR landscape rapidly expanding, now is the time to connect, collaborate, and shape the future of targeted oncology.

URLs:
Website: https://go.evvnt.com/3289243-0?pid=2874
Brochure: https://go.evvnt.com/3289243-3?pid=2874

Category: Conferences | Science, Health and Medicine | Pharmaceuticals

Prices:
Conference + Focus Day (3 Day Pass) - Drug Developer Pricing: USD 4197.00,
Conference Only - Drug Developer Pricing: USD 2999.00,
Conference + Focus Day (3 Day Pass) - Academic Pricing: USD 3597.00,
Conference Only - Academic Pricing: USD 2599.00,
Conference + Focus Day (3 Day Pass) - Solution Provider Pricing: USD 5097.00,
Conference Only - Solution Provider Pricing: USD 3699.00

Speakers: Jennifer Castro, Director of Translational and Discovery Biology, Accent Therapeutics, Michail Shipitsin, Vice President Biomarker Development, Acrivon Therapeutics, Ian Smith, Chief Medical Officer, Artios Pharma, Graeme Smith, Chief Scientific Officer, Artios Pharma, Angela Carvalho, Co-Founder and Chief Executive Officer, Beat Therapeutics, Michael Torres, CEO and Co-Founder, CrossBridge Bio, Alan D'Andrea, Director of the Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Luke Piggott, Director of Business Development and Principal Scientist, Debiopharm, Jatinder Mukker, Senior Director and Portfolio Section Head, Quantitative Pharmacology, EMD Serono, Jonathan Hollick, Project Leader, Evotec, Irena Konstantinova, Head of Biology, FoRx Therapeutics AG, Samuel Rabkin, Professor of Neurosciences, Harvard Medical School, Jann Sarkaria, Professor - Radiation Oncology, Mayo Clinic, Ioannis Gounaris, Vice President - Clinical Development, Merck KGaA, Ranjit Bindra, Co-Founder and Professor, Co-Director, Brain Tumor Center, Modifi Bio, Katherine Pawelczak, Chief Operating Officer and Vice President - Research, Nerx BioSciences Inc., Shridar Ganesan, Director, Center for Molecular Oncology, Perlmutter Cancer NYU Langone Health, Jack Cheng, Associate Director, PharmaEngine, Inc, Mads Daugaard, Co-founder, President and Chief Scientific Officer, Rakovina Therapeutics, Inc., Sotirios Sotiriou, Principal Scientist, Roche, Philip Beer, Chief Scientific Officer, Step Pharma, Yuka Kumagai, Senior Vice President, Head of Translational Research and Medicine, Sumitomo Pharma America, Inc., Tim Yap, Vice President and Head of Clinical Development, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Zakia Belaid-Sandal, Chief Executive Officer and Co-Founder, Theranovir, Anthony Chalmers, Professor and Clinical Oncology Chair, University of Glasgow, Ivan Ahel, EP Abraham Professor of Chemical Pathology, University of Oxford, David Mankoff, Professor and Vice-Chair for Research of Radiology; SAB Co-Chair, Trevar, University of Pennsylvania, Eric J. Brown, Associate Professor and Scientific Consultant, University of Pennsylvania, Hyunho Lee, Chief Technology Officer and Head of R and D, VSPharmTech, Wei Zhong, Chief Executive Officer, Wayshine Biopharm